ESMO Congress 2019
Ceritinib demonstrates efficacy in brain metastases in ALK+ NSCLC
Results from ASCEND-7 trial confirms the place of ceritinib as a standard treatment option for patients with ALK+ non-small-cell lung cancer and active brain metastases
From research bench to the patient’s bedside
ESMO Congress 2019 held in Barcelona, Spain, from 27 September to 1 October 2019
